在精神病患者和情绪障碍患者中, Teva Pharmaceuticals 的研究显示晚期运动障碍的诊断不同. Teva Pharmaceuticals' study reveals differing tardive dyskinesia diagnoses in psychotic versus mood disorder patients.
Teva制药公司介绍了其IMPACT-TD登记在2024年心理大会上的调查结果,着重指出了精神病患者和情绪紊乱患者在迟滞性抑郁症诊断方面的差异。 Teva Pharmaceuticals presented findings from its IMPACT-TD Registry at Psych Congress 2024, highlighting differences in tardive dyskinesia (TD) diagnoses between patients with psychotic and mood disorders. 虽然症状严重性相似,但诊断患有精神错乱症的病人患TD的病例较少。 While symptom severity was similar, fewer psychotic disorder patients were diagnosed with TD. 研究强调TD对生活质量的重大影响。 The study emphasizes the significant impact of TD on quality of life. 此外,病人对AUSTEDO XR的满意度很高,表明它在管理症状方面的有效性。 Additionally, patient satisfaction with AUSTEDO XR was high, indicating its effectiveness in managing symptoms.